🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for pancreatic ductal adenocarcinoma

A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab Advanced Therapies for Liver Metastases NCT04622423n/a1 site📍 Milan IRCCS San Raffaele Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082 AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers NCT07769502Phase 27 sites📍 Hattiesburg📍 Ramat Gan📍 Jerusalem AbbVie · Tests: Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma NCT07047807NA1 site📍 Boston Massachusetts General Hospital · Tests: PDAC-PATHWAYS, Usual Care A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017Phase 19 sites📍 Newport Beach📍 Miami📍 Detroit PanTher Therapeutics · Tests: PTM-101 A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840Phase 148 sites📍 Phoenix📍 Scottsdale📍 Duarte Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) A Study of LY4337713 in Participants With FAP-Positive Solid Tumors NCT07213791Phase 130 sites📍 Newport Beach📍 Stanford📍 Miami Eli Lilly and Company · Tests: LY4337713 Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals NCT06122896EARLY Phase 12 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Screening Blood Tests, Endoscopic Ultrasound, Magnetic Resonance Imaging, Magnetic Resonance Cholangiopancreatography Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer NCT06782932Phase 1, Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: AGEN2373, Balstilimab, Cyclophosphamide, GVAX, AGEN2373 (RP2D) Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031Phase 21 site📍 Beijing Guangzhou JOYO Pharma Co., Ltd · Tests: JYP0015 Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) NCT05346536NA1 site📍 Montpellier University Hospital, Montpellier · Tests: Detection of circulating tumor cells expressing Axl: CTC-AXL(+) Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma. NCT07148830NA1 site📍 Minya Minia University · Tests: Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy) Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07491445Phase 382 sites📍 Phoenix📍 Scottsdale📍 Los Angeles Revolution Medicines, Inc. · Tests: daraxonrasib, gemcitabine, nab-paclitaxel Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328Phase 3333 sites📍 Gilbert📍 Gilbert📍 Peoria NRG Oncology · Tests: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631Phase 19 sites📍 Princeton📍 Montreal📍 Odense C Novartis Pharmaceuticals · Tests: 68Ga-NNS309, 177Lu-DFC413 A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer NCT07324096NA1 site📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Computed Tomography with Contrast, Electronic Health Record Review BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT05688215Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biospecimen Collection, Computed Tomography, Core Biopsy, Fluorouracil, Irinotecan Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma NCT07259317Phase 220 sites📍 Scottsdale📍 Los Angeles📍 Orange Corcept Therapeutics · Tests: Relacorilant, Nab-paclitaxel, Gemcitabine Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC NCT07155850NA2 sites📍 Roma📍 London BetaGlue Therapeutics SpA · Tests: Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas Nutrition Intervention for Pancreatic Cancer NCT07554560NA2 sites📍 Philadelphia📍 Philadelphia Children's Hospital of Philadelphia · Tests: Structured Lipid Medical Food Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma NCT07096362Phase 21 site📍 Miami University of Miami · Tests: 5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Gemcitabine MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer NCT07045571n/a1 site📍 Shanghai Yingbin Liu, MD, PhD, FACS MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma NCT06648434Phase 11 site📍 St Louis Washington University School of Medicine · Tests: Zunsemetinib, mFOLFIRINOX PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma NCT04099134n/a1 site📍 Ulm University of Ulm Pancreatic Cancer Screening in a Population at High Risk NCT06330441NA1 site📍 Brno Masaryk Memorial Cancer Institute · Tests: endoscopic ultrasonography, magnetic resonance, laboratory examination
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy